Physician profile
Deepak Baskaran
NPI 1730135278
$23,431.35
in general payments reported to CMS, 2019-2025
56 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,727 · 2020: $3,238 · 2021: $4,104 · 2022: $3,718 · 2023: $3,745 · 2024: $2,698 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,445 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,444.89 |
| Education | $200.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,382.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,061.02 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,630.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,545.31 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $1,466.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $1,409.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,293.18 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,014.15 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $865.09 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $831.67 | 2019-2025 | |
| Amgen INC. | $746.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $658.95 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $608.78 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $547.39 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $451.28 | 2023-2025 | Gemtesa |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Baskaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.